When should patients with hepatitis B take tenofovir alafenamide fumarate tablets/Veride?

Tenofovir alafenamide fumarate tablets/Veride (TAF) developed byGilead Sciences is suitable for the treatment of adult hepatitis B (HBV) virus infection with compensated liver disease. Tenofovir alafenamide tablets were approved by the U.S. Food and Drug Administration (FDA) in 2016 and sold under the trade name Vemlidy.

Tenofovir alafenamide fumarate tablets are a once-daily 25 mg oral formulation for the treatment of adult patients with chronic HBV infection. Tenofovir alafenamide fumarate is a lipophilic, cell-penetrating compound that enters hepatocytes (liver cells) by passive diffusion and with the help of the hepatic uptake transporters OATP1B1 and OATP1B3. In hepatocytes, tenofovir alafenamide is hydrolyzed to tenofovir, which is phosphorylated to tenofovir diphosphate. Tenofovir diphosphate is integrated into viral DNA through HBV reverse transcriptase and inhibits viral growth by stopping HBV replication.

When hepatitis B virus infection causes liver inflammation and damage, doctors may recommend this drug to inhibit viral replication, thereby improving liver function and slowing disease progression. If the hepatitis B virus is actively replicating in the patient's body and the liver function is abnormal, the doctor may prescribe tenofovir alafenamide fumarate tablets to inhibit viral replication and protect the liver from further damage. Long-term chronic HBV infection may lead to the development of cirrhosis. In order to prevent or delay the progression of cirrhosis, doctors may recommend that patients take tenofovir alafenamide fumarate tablets to inhibit viral replication. If liver function continues to be abnormal in patients with hepatitis B and other treatments are ineffective, doctors may consider using tenofovir alafenamide to improve liver function.